標題: Titlebook: Cytochrome P450; In Vitro Methods and Zhengyin Yan,Gary W. Caldwell Book 2021 The Editor(s) (if applicable) and The Author(s), under exclus [打印本頁] 作者: Amalgam 時間: 2025-3-21 18:44
書目名稱Cytochrome P450影響因子(影響力)
書目名稱Cytochrome P450影響因子(影響力)學(xué)科排名
書目名稱Cytochrome P450網(wǎng)絡(luò)公開度
書目名稱Cytochrome P450網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cytochrome P450被引頻次
書目名稱Cytochrome P450被引頻次學(xué)科排名
書目名稱Cytochrome P450年度引用
書目名稱Cytochrome P450年度引用學(xué)科排名
書目名稱Cytochrome P450讀者反饋
書目名稱Cytochrome P450讀者反饋學(xué)科排名
作者: fleeting 時間: 2025-3-21 21:59 作者: 財產(chǎn) 時間: 2025-3-22 01:17
Quantitative Determination of Cytochrome P450 Using LC-MS/MS,reclinical, and individual data to population pharmacokinetics. For example, quantitative proteomics data can be utilized for in vitro-in vivo extrapolation (IVIVE), in vitro model validation, and determination of interindividual and species differences. Here, we describe a detailed methodology for 作者: resuscitation 時間: 2025-3-22 07:02
Spectral Quantitation of Total Cytochrome P450 in Microsomes Using a Single-Beam Spectrophotometer,obtaining the difference spectrum of the reduced form of cytochrome P450 subtracted from the spectrum of the carbon monoxide bound, reduced form. The resulting spectrum can then be analyzed to determine the difference between the absorbance at 450?nm and an isosbestic value (usually at 490?nm). The 作者: flourish 時間: 2025-3-22 09:08
Cytochrome P450 Enzyme Kinetics: Km and Vmax Determinations Using Metabolite Formation and Substratst important drug metabolizing enzymes (DMEs), which are responsible for converting structurally diverse exogenous xenobiotics to more water-soluble form to facilitate excretion from the body. By understanding the basic principles of kinetic, function, and mechanism of CYP enzymes will help to deter作者: 休戰(zhàn) 時間: 2025-3-22 16:53
Cytochrome P450 Inhibition Assay Using Human Liver Microsomes,y and development of new drugs, metabolic inhibitor drug interactions are important to consider since they can produce adverse effects. A robust LC/MS-based cytochrome P450 (CYP) inhibition assay using human liver microsomes has been fully developed and validated for major human CYPs, which could pr作者: 休戰(zhàn) 時間: 2025-3-22 20:19
Evaluation of Time-Dependent Cytochrome P450 Inhibition Using the Area Under the Curve Shift Methodor drug–drug interactions (DDIs). DDIs occur when one drug affects the metabolism of a coadministered drug. This changes the exposure and clearance of a coadministered drug. The consequences are a risk of therapeutic efficacy of a drug to severe adverse drug reactions, leading to death. Thus, it is 作者: gregarious 時間: 2025-3-22 23:15
Assessing Cytochrome P450 Time-Dependent Inhibition (IC50 Shift Assay) Using Both Diluted and Non-D is usually studied by measuring the half-maximal inhibitory concentration (IC50) shift of a drug candidate after a 30-min incubation with human liver microsomes (HLMs) in the presence and absence of NADPH. There are two main methods to assess the IC50 shift, dilution method, and non-dilution method作者: certitude 時間: 2025-3-23 05:14 作者: 碎石 時間: 2025-3-23 08:54 作者: 加花粗鄙人 時間: 2025-3-23 09:55 作者: 螢火蟲 時間: 2025-3-23 17:52 作者: Spartan 時間: 2025-3-23 18:28 作者: 勾引 時間: 2025-3-24 01:37 作者: 大笑 時間: 2025-3-24 04:11
Assessment of Cytochrome P450 Metabolic Clearance Using Hepatocyte Suspension,tochrome P450 (CYP)-mediated metabolism. Therefore, hepatic clearance is undeniably one of the most critical pharmacokinetic parameters. In the early stages of drug discovery, the in vitro hepatic metabolic stability assay carries great importance as it provides a time- and cost-effective route for 作者: aesthetician 時間: 2025-3-24 06:33
Cytochrome P450 Knock-Out Assay with Nonselective Inhibitors,an also play a similar role in the metabolism of drugs and other xenobiotics. Oftentimes, CYPs and non-CYP enzymes can share substrate specificity and collectively catalyze oxidative metabolic reactions of the same drug. Therefore, it is of importance in drug discovery to differentiate CYP-mediated 作者: genesis 時間: 2025-3-24 12:50
Differentiation of Cytochrome P450-Mediated from Non-CYP-Mediated Metabolism: Aldehyde Oxidase and as medicinal chemistry strategies evolve to reduce cytochrome P450 (CYP) related drug metabolism. Consequently, there is a need for a differentiation strategy for test compounds to be characterized from those of CYP and molybdenum-containing hydroxylases. Herein, general procedures to identify acti作者: jaunty 時間: 2025-3-24 16:20
In Vitro Reaction Phenotyping of Cytochrome P450 Enzymes,ity in order to assess clinical drug–drug interaction potential and estimate its relative contribution to the overall metabolic clearance in human. CYP phenotyping is commonly carried out using recombinant CYPs, and/or human liver microsomes (HLM) in combination with isoform-specific chemical inhibi作者: 不透明 時間: 2025-3-24 20:26 作者: 凹處 時間: 2025-3-25 02:12 作者: Offstage 時間: 2025-3-25 04:06 作者: 潛移默化 時間: 2025-3-25 08:01
Charging of New Energy Vehicles,ign and safety assessment of discovery compounds. There are several reported variations of GSH trapping assays, each with their own unique advantages and disadvantages. Here, we describe a simplified reactive metabolite screening assay optimized for semi-high throughput analysis of drug discovery candidates.作者: Indebted 時間: 2025-3-25 12:03
Cytochrome P450 Enzyme Kinetics: Km and Vmax Determinations Using Metabolite Formation and Substratorm to facilitate excretion from the body. By understanding the basic principles of kinetic, function, and mechanism of CYP enzymes will help to determine drug pharmacokinetic properties as well as to predict clinical drug–drug interaction.作者: chronology 時間: 2025-3-25 19:52
Cytochrome P450-Mediated Drug Bioactivation Assay: An Untargeted High Resolution Accurate Mass LC/Mign and safety assessment of discovery compounds. There are several reported variations of GSH trapping assays, each with their own unique advantages and disadvantages. Here, we describe a simplified reactive metabolite screening assay optimized for semi-high throughput analysis of drug discovery candidates.作者: CLEAR 時間: 2025-3-25 22:11
Annual Report on China’s Economic Growthovide useful data to design the clinical DDI studies. The half-maximal inhibitory concentration (IC50) value in the CYP inhibition assay is calculated by the decreased formation of metabolites compared to the vehicle control.作者: 爭吵 時間: 2025-3-26 00:29
Book 2021in selecting drug candidates in a drug discovery pipeline. Major factors affecting drug metabolism include CYP expression levels, kinetic parameters for individual CYP enzymes, CYP inhibition and induction, time-dependent inhibition (TDI), CYP stability, non-CYP stability, UDP-glucuronosyltransferas作者: 傻 時間: 2025-3-26 06:41 作者: Inelasticity 時間: 2025-3-26 11:25 作者: 侵蝕 時間: 2025-3-26 15:11
Fang Cai,Yongsheng Ma,Zhijun Jin incubation, and a lower concentration of HLMs can be used throughout the experiment. Here we describe both dilution and non-dilution methods to evaluate the time-dependent inhibition against CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 (midazolam and testosterone as substrate) in human liver microsomes.作者: CAMP 時間: 2025-3-26 20:53 作者: 向下五度才偏 時間: 2025-3-26 22:06
Guanhua Wang,Zhuo Fang,Xiaoyuan Xiaal tools to evaluate CYP induction and suppression. As described in this chapter, enzyme induction and suppression can be assessed by measuring P450 enzyme activity as well as mRNA in 3D spheroids culture.作者: gastritis 時間: 2025-3-27 01:10 作者: 清澈 時間: 2025-3-27 08:12
Characteristics of Major Drug Metabolizing Cytochrome P450 Enzymes, information to investigate the various CYP-related properties of xenobiotics in a drug discovery pipeline. Chapters .–. provide detailed CYP and non-CYP in vitro methods and protocols that can be easily established in drug discovery.作者: Androgen 時間: 2025-3-27 10:26
Evaluation of Time-Dependent Cytochrome P450 Inhibition Using the Area Under the Curve Shift Methodt activity remaining versus the inhibitor concentration plot. By producing in vitro TDI data, clinical DDI can be understood and predicted. In vitro testing helps predict in vivo results, as well as helps in the design or avoidance of clinical trials.作者: inquisitive 時間: 2025-3-27 16:02
Assessing Cytochrome P450 Time-Dependent Inhibition (IC50 Shift Assay) Using Both Diluted and Non-D incubation, and a lower concentration of HLMs can be used throughout the experiment. Here we describe both dilution and non-dilution methods to evaluate the time-dependent inhibition against CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 (midazolam and testosterone as substrate) in human liver microsomes.作者: 包庇 時間: 2025-3-27 20:40 作者: 配偶 時間: 2025-3-27 23:07 作者: 套索 時間: 2025-3-28 03:01 作者: 法官 時間: 2025-3-28 07:44 作者: 水槽 時間: 2025-3-28 12:45
Dieter Schallreuter,Eberhard Neumannam instrument where the total P450 enzyme is reduced by sodium dithionite prior to equilibration of the sample with carbon monoxide. Variations on the method to reduce the potentially confounding effects of hemoglobin contamination are also included.作者: fluffy 時間: 2025-3-28 17:45 作者: 關(guān)節(jié)炎 時間: 2025-3-28 19:29 作者: resilience 時間: 2025-3-29 00:56
Differentiation of Cytochrome P450-Mediated from Non-CYP-Mediated Metabolism: Aldehyde Oxidase and Additionally, identifying structural features that lend themselves to aldehyde oxidase and xanthine oxidoreductase metabolism, tissue fractions appropriate to measure activities of these enzymes, specific cofactors to add or omit, specific inhibitors, kinetic idiosyncrasies, and confirmatory studies are detailed.作者: Cosmopolitan 時間: 2025-3-29 06:07 作者: Condense 時間: 2025-3-29 09:13 作者: mechanical 時間: 2025-3-29 14:27 作者: 壟斷 時間: 2025-3-29 15:38
Annuaire Européen / European Yearbookof each major drug metabolizing CYPs, challenges still exist in terms of predictions for CYP-mediated Drug–Drug interactions (DDI), genetic variations, contributions to idiosyncratic drug-induced toxicity, and effects of CYP regulation in disease. New substrates for CYPs are discovered every day, re作者: Embolic-Stroke 時間: 2025-3-29 20:53
Commemorative and Obituary Notices,reclinical, and individual data to population pharmacokinetics. For example, quantitative proteomics data can be utilized for in vitro-in vivo extrapolation (IVIVE), in vitro model validation, and determination of interindividual and species differences. Here, we describe a detailed methodology for 作者: ANIM 時間: 2025-3-30 01:19 作者: 態(tài)學(xué) 時間: 2025-3-30 07:17 作者: goodwill 時間: 2025-3-30 09:15
Annual Report on China’s Economic Growthy and development of new drugs, metabolic inhibitor drug interactions are important to consider since they can produce adverse effects. A robust LC/MS-based cytochrome P450 (CYP) inhibition assay using human liver microsomes has been fully developed and validated for major human CYPs, which could pr作者: Esophagus 時間: 2025-3-30 13:32
Current Chinese Economic Report Seriesor drug–drug interactions (DDIs). DDIs occur when one drug affects the metabolism of a coadministered drug. This changes the exposure and clearance of a coadministered drug. The consequences are a risk of therapeutic efficacy of a drug to severe adverse drug reactions, leading to death. Thus, it is 作者: 嚴厲批評 時間: 2025-3-30 19:06 作者: 胎兒 時間: 2025-3-30 22:03
Current Chinese Economic Report Seriesl to produce DDIs. Experiments can be designed that recognize such entities by assessing receptor transactivation in cell-based systems and monitoring reporter gene activity. These in vitro assays have several advantages; activation of a specific nuclear receptor (NR) can be determined, there is a h作者: 明智的人 時間: 2025-3-31 04:17 作者: 共同生活 時間: 2025-3-31 08:08 作者: Lice692 時間: 2025-3-31 11:02 作者: 有花 時間: 2025-3-31 14:16
Guanhua Wang,Zhuo Fang,Xiaoyuan Xia in vitro liver model that resembles in vivo microenvironment with improved predictive capabilities is highly desirable. Historically, two-dimensional (2D) primary human hepatocyte (PHH) cultures have been used for the in vitro system to test a compound’s ability to induce or suppress cytochrome P45作者: Arthropathy 時間: 2025-3-31 20:42
https://doi.org/10.1007/978-981-99-7289-0m of a drug molecule is one way that a drug candidate can fail. Since most small molecules are metabolized by the liver, the enzymes in the liver need to be heavily accounted for. The majority of these enzymes are cytochrome P450 (CYP), and therefore screening compounds for activity with CYPs is nec作者: reject 時間: 2025-3-31 22:21
Yiming Yuan,Zhenkun Yan,Xuan Litochrome P450 (CYP)-mediated metabolism. Therefore, hepatic clearance is undeniably one of the most critical pharmacokinetic parameters. In the early stages of drug discovery, the in vitro hepatic metabolic stability assay carries great importance as it provides a time- and cost-effective route for 作者: 欺騙世家 時間: 2025-4-1 05:10
Yiming Yuan,Zhenkun Yan,Xuan Lian also play a similar role in the metabolism of drugs and other xenobiotics. Oftentimes, CYPs and non-CYP enzymes can share substrate specificity and collectively catalyze oxidative metabolic reactions of the same drug. Therefore, it is of importance in drug discovery to differentiate CYP-mediated 作者: infringe 時間: 2025-4-1 08:52 作者: 豐滿有漂亮 時間: 2025-4-1 12:37 作者: 親屬 時間: 2025-4-1 17:10 作者: Kidnap 時間: 2025-4-1 20:36
https://doi.org/10.1007/978-1-0716-1542-3Drug candidates; Therapeutic targets; CYP enzymes; Drug metabolites; Drug discovery and development; Meta作者: placebo-effect 時間: 2025-4-2 00:31
978-1-0716-1544-7The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Science+Busines作者: pineal-gland 時間: 2025-4-2 06:27 作者: SLAY 時間: 2025-4-2 09:58 作者: 百科全書 時間: 2025-4-2 11:49
Annuaire Européen / European Yearbookvery. Chapter . provides comprehensive information concerning CYP enzymes and their related metabolism properties on xenobiotics, while Chapters .–. provide detailed CYP and non-CYP in vitro methods and protocols that can be easily established in a drug discovery pipeline.作者: ADJ 時間: 2025-4-2 17:43
